CompletedPhase 2

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity

Lead sponsor

Zomagen Biosciences Ltd.

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

176

Study population

Obesity / overweight

Eligibility highlights

•BMI 30-42

Primary endpoint

•Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (Treatment-emergent AEs (any), Serious AEs (any), Discontinuation due to AE)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06771115

Org study IDVTX3232-204

Timeline

Milestones

Study start2025-01-07actual

Study first posted2025-01-13actual

Primary completion2025-09-10actual

Study completion2025-09-10actual

Last update posted2025-11-10actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Participants are male or female ≥ 18 years up to ≤ 80 years of age.

•Ability to comply with study requirements.

•BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening.

•Stable body weight (± 5%) for at least 3 months prior to screening.

•hs-CRP ≥ 2 mg/L at screening.

•Hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy.

•History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

•Obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity

•Have any prior diagnosis of diabetes mellitus

•Current participation (or within the last 3 months) in an organized weight reduction program.

•History or presence of clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass [bariatric] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity.

•Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.

•Use of any medication (e.g., GLP-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study.

•Receipt of the following medications:

1. Any immunosuppressive biologic or targeted therapy within 90 days prior to Day 1.

2. Use of anti-inflammatory medications within 30 days prior to Day 1

3. Colchicine within 30 days prior to Day 1.

4. Glucose-lowering agent(s) administered for conditions other than diabetes within 90 days before screening.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Safety / tolerability / PK

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

Change from baseline in hs-CRP level

Time frame:Day 1 of treatment period to week 12 of treatment period

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (SAE), and AEs leading to study treatment discontinuation through study completion

Time frame:Day 1 of treatment period through study completion, up to 16 weeks

descriptive

componentsTreatment-emergent AEs (any), Serious AEs (any), Discontinuation due to AE

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.